Abstract 1662
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of many commonly used chemotherapeutic agents, especially taxane-based regimen (Paclitaxel, nab-Paclitaxel, Docetaxel). The CIPN reduces patients health-related quality of life for years and often results in dose delay, dose reduction or treatment discontinuation. The prophylactic use of controlled cryotherapy (Hilotherapy®) prevents chemotherapy-induced-peripheral neuropathy (CIPN).
Methods
162 breast cancer patients treated with taxane based therapeutic regimen used prophylactic Hilotherapy® to cool hands and feet during chemotherapy infusion between 10/2016 – 02/2019. Hilotherapy® is a new physical thermotherapy device, equiped with hand and foot cuffs to allow a constant cooling in a localized and targeted manner. Continous cooling of hands and feet was performed 30 minutes before to 60 minutes after completing drug infusion with a temperature of 10-12 °C. CIPN symptoms were evaluated after each treatment cycle using common terminology criteria for adverse events (CTCAE). The sustainability of the impact was assessed by long-term datas (Follow Up patient contact every 3 months).
Results
122 patients have finished their chemotherapy treatments with prophylactic hand-feet cooling using Hilotherapy®, 39 patients are still under therapy. 113 patients (92.6%) developed none or mild symptoms of CIPN (grade 0-1). 8 patients (6,6%) reported grade 2 toxicity, 1 patient grade 3 (0,8%). The symptoms of CIPN were reversible. Four weeks after the last chemotherapy treatment, 5 patients (4,5%) still reported grade 2 toxicity, none of them suffered from grade 3. Another 3 months later, 2 patients (2,2%) reported an intermittent toxicity of grade 2. Long-term Follow Up datas confirm the lasting results.
Conclusions
Prophylactic Hilotherapy® prevented limiting CIPN Symptoms (> grade 1) in 93% of patients. 7% of the patients developed reversible toxicities grade 2/3. 4 months after chemotherapy treatment, all patients were without any limiting symptoms (grade ≤ 1), except two patients (grade 2). No dose modifications or treatment interruptions had been necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hilotherm GmbH.
Disclosure
T. Schaper: Honoraria (self), Advisory / Consultancy: Paxman; Honoraria (self), Travel / Accommodation / Expenses: Hilotherm; Honoraria (self), Advisory / Consultancy: EAoS; Honoraria (self): Roche. M. Darsow: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract